INHIBIKASE THERAPEUTICS INC (IKT)

US45719W2052 - Common Stock

1.99  +0.45 (+29.22%)

After market: 1.99 0 (0%)

Unregistered users can only see 4 years or quarters

Examples of complete financials are available for MSFT and AAPL.

Please register or login for additional data.

2023
(2023-12-31)
2022
(2022-12-31)
2021
(2021-12-31)
2020
(2020-12-31)
2019
(2019-12-31)
Revenue
260.50K120.00K3.10M700.00K1.12M
Operating Expenses
20.35M18.25M17.87M3.52M6.82M
Research and Development
13.62M12.03M11.36M890.00K2.55M
Selling, General, and Administrative Expenses
6.73M6.22M6.51M2.62M4.27M
Operating Income
-20.09M-18.13M-14.77M-2.82M-5.70M
Interest Income/Expense
1.06M70.00K-20.00K-30.00K-20.00K
Income Before Taxes
-19.03M-18.05M-14.79M-2.85M-5.72M
Net Income
-19.03M-18.05M-14.79M-2.85M-5.72M
EBITDA
-19.91M-18.12MN/AN/AN/A
 
Per Share Data
EPS Diluted Total Ops
-3.57-4.30-3.53-2.08-3.67
Non GAAP EPS
-3.57-4.32N/AN/AN/A
 
Statistics
Profit Margin
-7304.75%-15041.67%-477.10%-407.14%-510.71%
Operating Profit Margin
-7712.01%-15108.33%-476.45%-402.86%-508.93%

All data in USD

Charts